The findings of several recent studies have indicated that OLFML3, EVA1B, and FERMT3 are potential prognostic markers for glioma [40–42], which are significantly associated with poor prognosis and tumor immune microenvironment. This evidence concerns the gene OLFML3 and central nervous system cancer.